癌痛平胶囊治疗癌性疼痛的临床研究

目的探讨癌痛平胶囊治疗癌性疼痛的疗效和作用机理。方法60例患者随机分为两组，治疗组(30例，口服癌痛平胶囊)、对照组(30例，口服舒尔芬片)，治疗1周，观察两组患者疼痛相关情况，血浆β-内啡肽(β-EP)、环核苷酸(cAMP)水平，血液流变学指标、生活质量的改善以及药物不良反应发生率等情况。结果总有效率治疗组为90．0％，对照组为83．3％，两组，临床疗效比较差异无显著性。在减轻疼痛强度、减少疼痛次数、缩短疼痛持续时间和止痛作用起效时间，延长止痛作用维持时间，减少压痛、叩痛积分，提高血浆β—EP、降低cAMP水平等方面，两组治疗前后比较差异均有显著性(P<0．05或P<0．01)，治疗组在改善生活质量、改善血液流变学指标及不良反应发生等方面明显均优于对照组(P<0．05或P<0．01)。结论癌痛平胶囊治疗癌性疼痛疗效肯定，其镇痛作用可能与提高血浆β—EP含量、降低cAMP水平、改善血液流变学指标有关。

Clinical Study on Aitongping Capsule in Treating Cancerous Pain

OBJECTIVE: To explore the therapeutic effect and mechanism of Aitongping capsule (ATP) in treating cancerous pain. METHODS: Sixty cancer patients were randomly divided into two groups, 30 patients in the treated group took ATP and 30 patients in the control group took diclofenac, 1 week of treatment was applied. The relevant clinical conditions of cancerous pain, the content of plasma beta-endorphin (beta-EP) and c-AMP, hemorheological index, improuement of life quality of patients, occurrence rate of adverse reaction were observed before and after treatment. RESULTS: The total effective rate in the treated group and in the control group was 90.0 % and 83.3%, respectively, difference between them showed no significance. However, there were significant difference between the two groups in such aspects as the degree of pain relieving, the decrease of pain episodes, the shortening persistent time of pain and the initiation time of analgesic action and prolonged analgesic duration, the decrease of tenderness and percussion pain, the increase of plasma beta-EP content and the decrease of cAMP (P< 0.05 or P< 0.01). The evidences also showed that it was better in improving quality of life, ameliorating hemorheologic indexes and reducing incidence of adverse reaction in the treated group than in the control group (P <0.05 or P <0.01). CONCLUSION: ATP has affirmative effect on cancerous pain, its analgesic effect may be associated with the increasing of plasma beta-EP content, decreasing of cAMP level and ameliorating of hemorheologic indexes.